Clinical Trials Sponsored by Sound Pharmaceuticals, Incorporated

Total 270 results

Sound Pharmaceuticals, Incorporated

Completed

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Meniere's Disease

United States
Sound Pharmaceuticals, Incorporated

Enrolling by invitation

SPI-1005 Treatment in Moderate COVID-19 Patients

Coronavirus Infection | Covid19 | Corona Virus Infection | Coronavirus

United States
Sound Pharmaceuticals, Incorporated

Active, not recruiting

SPI-1005 for the Treatment of Meniere's Disease (STOPMD-3)

Meniere Disease | Ménière

United States
Sound Pharmaceuticals, Incorporated

Enrolling by invitation

SPI-1005 Treatment in Severe COVID-19 Patients

Coronavirus Infection | Covid19 | Corona Virus Infection | Coronavirus

United States
Sound Pharmaceuticals, Incorporated

Completed

SPI-1005 for the Treatment of Patients With Meniere's Disease

Meniere's Disease

United States
Sound Pharmaceuticals, Incorporated

Unknown

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss (PANIHL)

Noise Induced Hearing Loss

United States
Sound Pharmaceuticals, Incorporated

Completed

Study to Evaluate the Safety and Pharmacokinetics of SPI-1005

Cancer | Hearing Loss

United States
Sound Pharmaceuticals, Incorporated
VA Puget Sound Health Care System

Unknown

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Head and Neck Cancer | Lung Cancer | Hearing Loss | Ototoxicity | Tinnitus | Neuropathy

United States
Sound Pharmaceuticals, Incorporated
Med-El Corporation

Not yet recruiting

SPI-1005 in Adults Receiving Cochlear Implant

Hearing Loss | Cochlear Trauma
Sound Pharmaceuticals, Incorporated
University of Florida

Completed

Otoprotection With SPI-1005 for Prevention of Temporary Auditory Threshold Shift

Temporary Auditory Threshold Shift

United States
University of Oxford
Medical Research Council; Sound Pharmaceuticals, Incorporated

Recruiting

IMPase in Treatment-resistant Depression (OxIMP)

Depressive Disorder, Treatment-Resistant

United Kingdom
University of Oxford
Stanley Medical Research Institute; Sound Pharmaceuticals, Incorporated

Completed

Ebselen as an add-on Treatment in Hypo/Mania

Bipolar Disorder | Bipolar Disorder, Manic

United Kingdom
Sound Pharmaceuticals, Incorporated
Medical University of South Carolina; Cystic Fibrosis Foundation

Enrolling by invitation

SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

Ototoxicity

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Hepatitis C

Australia, Canada, France, Italy, Poland, United Kingdom, Germany, United States, Spain, Israel, Argentina, Puerto Rico, Austria
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Virology Follow up Study in Subjects Previously Treated With Telaprevir

Hepatitis C

United States, France, Canada, Germany, Puerto Rico
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Qilu Puget Sound Biotherapeutics (dba Sound Biologics)
Pharmaceutical Research Associates

Unknown

A Study of PSB205 in Subjects With Advanced Solid Tumors

Neoplasm Malignant

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) (Galileo)

Myotonic Dystrophy Type 1 (DM1)

Canada
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)

Painful Lumbosacral Radiculopathy

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Phase 1, First-in-human Study of VX-828

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Type 1 Diabetes

United States, Italy, Canada, Switzerland, Netherlands, Germany, United Kingdom
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype

Alpha-1 Antitrypsin Deficiency

United States, United Kingdom, Germany, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Cystic Fibrosis

United States, Germany, United Kingdom, Canada, Australia, Switzerland, France, Ireland, Belgium, Denmark, Poland
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Enrolling by invitation

A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Pharmacokinetic Drug-drug Interactions Between VX-548, Midazolam, and Digoxin

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-668

Alpha-1 Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1, First-in-human Study of VX-634

Alpha 1-Antitrypsin Deficiency

United States
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age

Cystic Fibrosis

United States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Cystic Fibrosis

United States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Cystic Fibrosis

United States, Australia, Canada, France, United Kingdom, Germany, Spain, Switzerland, Belgium, Israel, Netherlands, Denmark, Italy, Austria, Ireland, Sweden
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

Focal Segmental Glomerulosclerosis (FSGS)

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Cystic Fibrosis

United States, Canada, United Kingdom, Australia, Ireland
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

France, Spain, Belgium, Netherlands, Australia, Italy, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants

Acute Pain

United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Netherlands, United Kingdom, Germany, Portugal
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy

Acute Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Australia, France, Germany, Italy, Czechia, Austria, Sweden, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants

APOL1-mediated Kidney Disease

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

Cystic Fibrosis

Netherlands, United Kingdom
Vertex Pharmaceuticals Incorporated

Terminated

Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype

Alpha 1-Antitrypsin Deficiency

United States, Germany, Canada, Ireland
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom

Clinical Trials Sponsored by Sound Pharmaceuticals, Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations